Search
forLearn
5 / 801 resultslearn Setipiprant
learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
learn Prednisolone
Research
5 / 1000+ results
research Sudden Akathisia After a Ziprasidone Dose Reduction
Lowering the dose of ziprasidone can cause sudden restlessness and urge to move in patients.
research Adverse Cutaneous Reactions to Antipsychotics
Some patients taking antipsychotic medications experience skin reactions, ranging from mild to severe.
research Improvement of General Symptoms in a Chronic Psychotic Patient Treated with Finasteride: Case Report
Finasteride improved symptoms in a schizophrenia patient.
research Treatment of Delusional Infestation with Olanzapine
Olanzapine helped a man who thought he had bugs on his skin.
research Impulse Control Disorders
The book provides comprehensive information on Impulse Control Disorders but lacks definitive evidence for effective treatments.
Community Join
5 / 1000+ resultscommunity Pyrludimide (KX-826) or Breezula (clascoterone)
The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.
community Pyrilutamide: Increased libido. Anyone else experienced something similar with either RU or Pyri?
An increase in libido associated with the use of Pyri, and a discussion about how it may be working comparably to other hair loss treatments such as RU58841, Finasteride and Minoxidil.
community Pyrilutamide Phase 3 on its way
Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
community Ru58841 and pyrilutamid receptor binding affinity vs spironolactone?
Female considering adding topical anti-androgen, seeks advice on RU58841 or pyrilutamid's binding affinity compared to spironolactone.
community The story of RU58841/PSK3841
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.